Rationale and use of antiplatelet and antithrombotic drugs during cardiovascular interventions: May 2010 update

EuroIntervention. 2010 May;6(1):39-45.
No abstract available

Publication types

  • Practice Guideline

MeSH terms

  • Acute Coronary Syndrome / therapy*
  • Aged
  • Angioplasty, Balloon, Coronary* / adverse effects
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Evidence-Based Medicine
  • Fibrinolytic Agents / administration & dosage*
  • Fibrinolytic Agents / adverse effects
  • Hemorrhage / chemically induced
  • Humans
  • Myocardial Infarction / therapy*
  • Platelet Aggregation Inhibitors / administration & dosage*
  • Platelet Aggregation Inhibitors / adverse effects
  • Risk Assessment
  • Thrombosis / etiology
  • Thrombosis / prevention & control*
  • Time Factors
  • Treatment Outcome

Substances

  • Fibrinolytic Agents
  • Platelet Aggregation Inhibitors